The question is still whether a GLP-1 is the right tool for this patient at this time, for the reasons that already justify the decision
Lyons SK, Hermann JM, Miller KM et al (2017) Use of adjuvant pharmacotherapy in type 1 diabetes: international comparison of 49,996 individuals in the prospective diabetes follow-up and T1D exchange registries
Still, nice results
10.1016/j.theriogenology.2016.02.034 2
Over the past year, more patients have come to us asking about Ozempic (semaglutide) and similar GLP-1 receptor agonists for their role in weight loss but also for effects on the musculoskeletal system, especially joint pain, bone density, and muscle preservation
If you have high cardiovascular risk or a family history of early heart disease, discuss L-carnitine with your clinician before starting